Perigon Wealth Management LLC Grows Stake in Eli Lilly and Company $LLY

Perigon Wealth Management LLC raised its position in shares of Eli Lilly and Company (NYSE:LLY) by 2.8% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 37,419 shares of the company’s stock after purchasing an additional 1,028 shares during the period. Perigon Wealth Management LLC’s holdings in Eli Lilly and Company were worth $28,551,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds have also made changes to their positions in the company. Brighton Jones LLC grew its holdings in Eli Lilly and Company by 22.0% during the 4th quarter. Brighton Jones LLC now owns 9,597 shares of the company’s stock worth $7,409,000 after acquiring an additional 1,730 shares in the last quarter. Revolve Wealth Partners LLC lifted its position in shares of Eli Lilly and Company by 2.8% in the 4th quarter. Revolve Wealth Partners LLC now owns 1,471 shares of the company’s stock worth $1,136,000 after purchasing an additional 40 shares during the period. Driehaus Capital Management LLC boosted its stake in shares of Eli Lilly and Company by 73.2% during the first quarter. Driehaus Capital Management LLC now owns 1,675 shares of the company’s stock valued at $1,383,000 after purchasing an additional 708 shares in the last quarter. Armistice Capital LLC purchased a new position in Eli Lilly and Company during the first quarter valued at approximately $260,000. Finally, Ameriflex Group Inc. raised its stake in Eli Lilly and Company by 138.4% in the first quarter. Ameriflex Group Inc. now owns 1,118 shares of the company’s stock worth $923,000 after buying an additional 649 shares in the last quarter. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on LLY. Weiss Ratings reiterated a “buy (b-)” rating on shares of Eli Lilly and Company in a report on Monday, December 22nd. Wolfe Research lifted their target price on Eli Lilly and Company from $1,050.00 to $1,250.00 and gave the company an “outperform” rating in a research note on Wednesday, December 3rd. Truist Financial increased their price target on shares of Eli Lilly and Company from $1,038.00 to $1,182.00 and gave the company a “buy” rating in a research report on Wednesday, November 19th. Wall Street Zen raised shares of Eli Lilly and Company from a “buy” rating to a “strong-buy” rating in a research report on Saturday, November 1st. Finally, The Goldman Sachs Group increased their target price on shares of Eli Lilly and Company from $951.00 to $1,145.00 and gave the company a “buy” rating in a research report on Monday, December 15th. Four analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and five have given a Hold rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $1,155.36.

Eli Lilly and Company Trading Up 0.1%

Shares of Eli Lilly and Company stock opened at $1,078.72 on Tuesday. The firm’s 50 day simple moving average is $992.14 and its two-hundred day simple moving average is $843.49. The firm has a market capitalization of $1.02 trillion, a price-to-earnings ratio of 52.78, a PEG ratio of 1.09 and a beta of 0.37. Eli Lilly and Company has a 12-month low of $623.78 and a 12-month high of $1,111.99. The company has a current ratio of 1.55, a quick ratio of 1.24 and a debt-to-equity ratio of 1.71.

Eli Lilly and Company (NYSE:LLY) last posted its quarterly earnings data on Thursday, October 30th. The company reported $7.02 EPS for the quarter, topping the consensus estimate of $6.42 by $0.60. Eli Lilly and Company had a net margin of 30.99% and a return on equity of 109.52%. The business had revenue of $17.60 billion during the quarter, compared to the consensus estimate of $16.09 billion. During the same period in the previous year, the firm posted $1.18 earnings per share. The business’s revenue for the quarter was up 53.9% compared to the same quarter last year. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. Analysts predict that Eli Lilly and Company will post 23.48 EPS for the current year.

Eli Lilly and Company Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Friday, February 13th will be issued a $1.73 dividend. This is a boost from Eli Lilly and Company’s previous quarterly dividend of $1.50. This represents a $6.92 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date of this dividend is Friday, February 13th. Eli Lilly and Company’s dividend payout ratio is currently 33.86%.

Eli Lilly and Company Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.